Drug Profile


Alternative Names: Ceoxx; MK 966; Vioxx; Vioxx Acute

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Banyu; CollaGenex Pharmaceuticals; Merck & Co; Merck Frosst
  • Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Dental pain; Dysmenorrhoea; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatoid arthritis
  • Discontinued Alzheimer's disease; Colorectal cancer; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Migraine; Periarthritis; Preterm labour; Sporadic adenomas

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Feb 2005 An advisory committee of the FDA has recommended that the risk-benefit profile for rofecoxib supports marketing in the USA
  • 11 Oct 2004 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top